Rank #1420ORIC

Oric Pharmaceuticals, Inc.

$11.33

4.62% (Daily)

Market Cap

$1.10B

Revenue

$N/A

Rank by MCap

#1420

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Richard A. Heyman Ph.D.

Headquarters

South San Francisco, CA

Employees

106

About Oric Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exo...